Featured in Journal of Clinical Trials, Volume 7, pages 60-61
Gavin Morgan, Manager of Global Logistics
Over the last ten years, the way that the pharmaceutical industry is expected to deliver new drug products to market has seen symbolic change. This shift in process has been driven by a number of significant factors.
In the next five years the industry expected to lose around $290b in revenue from branded prescription medications going off patent (the Patent Cliff) and overall drug development timelines are coming under continued scrutiny. Internal and external pressures mean traditional approaches to drug development are difficult to sustain and speed to market is paramount to success.